Vivesto is focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. The company has a pipeline of preclinical- and clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) was developed for ovarian cancer patients, and US Elevar Therapeutics, Inc. is responsible for commercialization and sales via a global partnership. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and Docetaxel micellar, in development for advanced prostate cancer. Vivesto has its own proprietary drug delivery technology designed to improve solubility of drugs as well as efficacy and safety.